697PA phase I, open-label, multi-center, dose-escalation study of codrituzumab, an anti-glypican-3 monoclonal antibody, in combination with atezolizumab in patients with locally advanced or metastatic hepatocellular carcinoma. (23rd October 2018) - Cheng, A-L; Yen, C-J; Okusaka, T; Ikeda, M; Hsu, C-H; Wu, S-Y; Morizane, C; Hashimoto, Y; Ueshima, K; Ohtomo, T; Tanaka, T; Kudo, M